A new report released today by the Department of Health and Human Services outlines the Biden Administration’s plans to address high drug prices. The report recommends the pursuit of legislation that would enable price negotiation in Medicare Parts B and D, with those negotiated prices also available to the federal marketplace, commercial plans and employers who want to participate; Medicare Part D reform, including a cap on beneficiary out-of-pocket spending; and legislation that would slow price increases over time on existing drugs and speed entry of biosimilars and generics to the marketplace while increasing their prescribing by clinicians.   
  
The report also suggests a series of executive tools to be undertaken by HHS, including the testing of several models that would use value-based payments in Medicare Part B or provide additional cost-sharing support for Medicare Part D Low-income Subsidy Beneficiaries for using biosimilars or generics, as well as efforts to curb the use of anti-competitive tactics like pay-for-delay and evergreening. A separate test of cost-of-care models would look at whether such efforts can produce changes in drug utilization, reduce total spending and improve patient outcomes. 
  
The report restates the Administration’s continued support of the 340B Drug Pricing Program. 
 

Related News Articles

Headline
The AHA today restated its strong support for the Centers for Medicare & Medicaid Services’ withdrawal of its Most Favored Nation Model proposed rule. In…
Headline
President Biden today urged Congress to allow Medicare to negotiate prescription drug prices and cap the amount beneficiaries pay out-of-pocket for drugs each…
Headline
The Senate Judiciary Committee Subcommittee on Competition Policy, Antitrust, and Consumer Rights yesterday held a hearing on surging drug prices and…
Headline
Fourteen leading U.S. drug companies from 2016 to 2020 spent $577 billion on stock buybacks and dividends, $56 billion more than they spent on research…
Headline
The Department of Health and Human Services today withdrew requests for proposals on ways individuals could import prescription drugs from other countries…
Headline
The AHA July 2 expressed support for the Drug-Price Transparency for Consumers Act of 2021 (S.2304).    “America’s hospitals and health systems are…